Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NVTA, BLFS, EXAS, PACB, FATE, and represent 32.31% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: MXCT (+$171M), SLGC (+$154M), ABSI (+$90M), DNA (+$84M), PACB (+$76M), TNYA (+$74M), TNGX (+$71M), SMFR (+$38M), ALLO (+$23M), SRPT (+$20M).
- Started 8 new stock positions in VRTX, MXCT, SMFR, DNA, TNYA, TNGX, SLGC, ABSI.
- Reduced shares in these 10 stocks: AMRS (-$49M), Constellation Pharmceticls I (-$45M), NEO (-$22M), FULC (-$12M), CLOV (-$9.7M), ME (-$8.2M), GBIO (-$7.2M), SGMO (-$6.6M), TPTX (-$5.9M), NAUT.
- Sold out of its positions in AMRS, CLOV, Constellation Pharmceticls I, FULC, NEO, SGMO, TPTX, ZY.
- Casdin Capital was a net buyer of stock by $690M.
- Casdin Capital has $4.0B in assets under management (AUM), dropping by 1.98%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Casdin Capital
Companies in the Casdin Capital portfolio as of the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Invitae (NVTA) | 8.6 | $347M | 12M | 28.43 | ||
| Biolife Solutions Com New (BLFS) | 8.0 | $320M | 7.6M | 42.32 | ||
| EXACT Sciences Corporation (EXAS) | 5.6 | $225M | 2.4M | 95.45 | ||
| Pacific Biosciences of California (PACB) | 5.1 | $204M | +59% | 8.0M | 25.55 | |
| Fate Therapeutics (FATE) | 5.0 | $202M | 3.4M | 59.27 | ||
| Alnylam Pharmaceuticals (ALNY) | 4.7 | $189M | 1.0M | 188.81 | ||
| Maxcyte (MXCT) | 4.2 | $171M | NEW | 14M | 12.21 | |
| Blueprint Medicines (BPMC) | 4.0 | $159M | 1.6M | 102.81 | ||
| Somalogic Class A Com (SLGC) | 3.8 | $154M | NEW | 12M | 12.39 | |
| Verve Therapeutics (VERV) | 3.6 | $143M | 3.0M | 47.00 | ||
| Relay Therapeutics (RLAY) | 2.9 | $116M | +8% | 3.7M | 31.53 | |
| Twist Bioscience Corp (TWST) | 2.7 | $107M | 1.0M | 106.97 | ||
| Sarepta Therapeutics (SRPT) | 2.5 | $102M | +24% | 1.1M | 92.48 | |
| Codexis (CDXS) | 2.5 | $101M | 4.3M | 23.26 | ||
| Agios Pharmaceuticals (AGIO) | 2.5 | $100M | 2.2M | 46.15 | ||
| Absci Corp (ABSI) | 2.2 | $90M | NEW | 7.7M | 11.63 | |
| Denali Therapeutics (DNLI) | 2.1 | $86M | +5% | 1.7M | 50.45 | |
| Ginkgo Bioworks Holdings Cl A Shs (DNA) | 2.1 | $84M | NEW | 7.2M | 11.59 | |
| Century Therapeutics (IPSC) | 2.0 | $81M | 3.2M | 25.16 | ||
| Revolution Medicines (RVMD) | 1.9 | $77M | +21% | 2.8M | 27.51 | |
| Caredx (CDNA) | 1.9 | $76M | 1.2M | 63.37 | ||
| Tenaya Therapeutics (TNYA) | 1.8 | $74M | NEW | 3.6M | 20.65 | |
| Beam Therapeutics (BEAM) | 1.8 | $71M | 819k | 87.01 | ||
| Tango Therapeutics (TNGX) | 1.8 | $71M | NEW | 5.5M | 12.93 | |
| Dermtech Ord ord (DMTK) | 1.4 | $56M | 1.7M | 32.11 | ||
| Beigene Sponsored Adr (BGNE) | 1.4 | $55M | 150k | 363.00 | ||
| Allogene Therapeutics (ALLO) | 1.3 | $54M | +71% | 2.1M | 25.70 | |
| Global Blood Therapeutics In (GBT) | 1.2 | $49M | +46% | 1.9M | 25.48 | |
| Adaptive Biotechnologies Cor (ADPT) | 1.2 | $49M | 1.4M | 33.99 | ||
| Sema4 Holdings Corp Com Cl A (SMFR) | 0.9 | $38M | NEW | 5.0M | 7.59 | |
| Alector (ALEC) | 0.9 | $38M | 1.7M | 22.82 | ||
| Generation Bio (GBIO) | 0.8 | $33M | -17% | 1.3M | 25.07 | |
| Singular Genomics Systems In (OMIC) | 0.8 | $30M | 2.7M | 11.19 | ||
| 4d Molecular Therapeutics In (FDMT) | 0.7 | $30M | 1.1M | 26.97 | ||
| Crispr Therapeutics Namen Akt (CRSP) | 0.7 | $30M | 266k | 111.93 | ||
| Magenta Therapeutics (MGTA) | 0.7 | $28M | +16% | 3.9M | 7.28 | |
| Syndax Pharmaceuticals (SNDX) | 0.6 | $23M | 1.2M | 19.11 | ||
| Monte Rosa Therapeutics (GLUE) | 0.5 | $21M | 961k | 22.28 | ||
| Zai Lab Adr (ZLAB) | 0.5 | $20M | 190k | 105.39 | ||
| 23andme Holding Class A Com (ME) | 0.4 | $17M | -32% | 1.8M | 9.06 | |
| 908 Devices (MASS) | 0.3 | $13M | 407k | 32.52 | ||
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.3 | $13M | 548k | 23.01 | ||
| Oric Pharmaceuticals (ORIC) | 0.3 | $13M | 602k | 20.91 | ||
| Kronos Bio (KRON) | 0.3 | $12M | 583k | 20.96 | ||
| Vertex Pharmaceuticals Incorporated Call Option (VRTX) | 0.2 | $9.1M | NEW | 50k | 181.40 | |
| Decibel Therapeutics (DBTX) | 0.2 | $9.0M | 1.2M | 7.71 | ||
| Alpha Teknova (TKNO) | 0.2 | $7.5M | 300k | 24.89 | ||
| Orchard Therapeutics Ads (ORTX) | 0.1 | $5.9M | -19% | 2.6M | 2.30 | |
| Seer Com Cl A (SEER) | 0.1 | $5.2M | 150k | 34.53 | ||
| Berkeley Lts (BLI) | 0.1 | $3.9M | 200k | 19.56 | ||
| Stoke Therapeutics (STOK) | 0.1 | $3.1M | 120k | 25.44 | ||
| Foghorn Therapeutics (FHTX) | 0.1 | $3.0M | 215k | 13.93 | ||
| Nautilus Biotechnology (NAUT) | 0.0 | $1.4M | -55% | 225k | 6.14 | |
| Sana Biotechnology (SANA) | 0.0 | $1.4M | 60k | 22.52 |
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2021 Q3 filed Nov. 15, 2021
- Casdin Capital 2021 Q2 filed Aug. 16, 2021
- Casdin Capital 2021 Q1 filed May 17, 2021
- Casdin Capital 2020 Q4 filed Feb. 16, 2021
- Casdin Capital 2020 Q3 filed Nov. 16, 2020
- Casdin Capital 2020 Q2 filed Aug. 14, 2020
- Casdin Capital 2020 Q1 filed May 15, 2020
- Casdin Capital 2019 Q4 filed Feb. 14, 2020
- Casdin Capital 2019 Q3 restated filed Jan. 3, 2020
- Casdin Capital 2019 Q3 filed Nov. 12, 2019
- Casdin Capital 2019 Q3 amended filed Nov. 12, 2019
- Casdin Capital 2019 Q2 filed Aug. 13, 2019
- Casdin Capital 2019 Q1 filed May 15, 2019
- Casdin Capital 2018 Q4 filed Feb. 13, 2019
- Casdin Capital 2018 Q3 filed Nov. 14, 2018
- Casdin Capital 2018 Q2 restated filed Aug. 20, 2018